How to appeal a Humana atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for atopic dermatitis (ad / eczema)

Cited policy: Humana Cibinqo (Abrocitinib) for Moderate-Severe AD PA

Age >=12 yr per Feb 2023 expansion. Moderate-severe AD. Step-therapy: failure of topical + (Dupixent OR systemic immunosuppressant OR phototherapy). JAK boxed-warning screening per FDA: TB, HBV/HCV, lipids, malignancy, VTE, smoking, MACE. Start 100 mg PO daily; escalate 200 mg if inadequate response.

How Humana denies atopic dermatitis (ad / eczema) — and how to counter it

Where Humana pushes back: 1) JAK black-box → 2 biologic failures required; 2) Try Rinvoq first.

Counter-arguments that hold up: ORAL Surveillance generalization to AD population is inappropriate (RA-specific, IL-6-dependent, older + higher CV risk). JADE MONO-1/-2 (Simpson Lancet 2020), JADE COMPARE (Bieber NEJM 2021 — abrocitinib 200 mg SUPERIOR to dupilumab on EASI-90 + itch at 12 wk), JADE TEEN (Eichenfield JAAD 2021), JADE REGIMEN show favorable risk-benefit in AD. Cibinqo and Rinvoq are PARALLEL JAK1 options — no preference order in AAD 2024 + AAAAI 2023. Both indicated ages 12+. Document JAK risk screening complete (TB / lipids / VTE hx).

What Humana typically denies for atopic dermatitis (ad / eczema)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.